Work

ENP 2017–2022 in Île-de-France: prevalence of healthcare-associated infections (HAIs) and antibiotic use.

Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Introduction / ObjectiveNational point prevalence surveys (NPS) are conducted every five years in all public and private healthcare facilities to measure the prevalence of healthcare-associated infections (HAIs) and antibiotic treatments among hospitalised patients. The objective was to compare changes in prevalence in Île-de-France between 2017 and 2022.Materials and MethodsHealthcare facilities were included in the study if they had participated in both surveys, and wards were included if they had enrolled at least 10 patients. Patient characteristics, HAIs and antibiotic treatments collected according to the NPS protocol were compared. COVID-19 infections in 2022 were excluded from the analysis, except in cases of co-infection with an HAI.ResultsAmong the 79 healthcare facilities, 19,211 patients were included in 2017 and 16,266 in 2022. In 2022, there were more immunocompromised patients (17.5% vs 16.2%, p=0.001) and more patients with an invasive device (48.1% vs 42.6%, p<0.001).The prevalence of infected patients (6.3% and 6.4%, respectively) and of HAIs (6.7% in both years) did not differ significantly between 2022 and 2017. The prevalence of pneumonia was higher in 2022 (19.8% vs 16.1%, p=0.03). The median time to HAI acquisition was not significantly different (approximately 14 days). Among patients with at least one HAI, the proportions receiving antibiotics (94% vs 91%), with a urinary catheter (30% vs 26%), and with a PICC line (6% vs 4%) were higher in 2022 (p<0.01 for all three comparisons).The prevalence of patients receiving at least one antibiotic was not significantly different in 2022 compared with 2017 (21.1% vs 20.3%, respectively; p=0.075). The proportion of patients receiving antibiotic monotherapy was higher in 2022 (73%) than in 2017 (70%), p=0.01. Among prescriptions, those issued for community-acquired infections were more frequent in 2022 (54% vs 52%) (p=0.005), whereas those prescribed for HAIs were similar in both years (26%). The main agents prescribed were amoxicillin/clavulanic acid, ceftriaxone, co-trimoxazole and amoxicillin (approximately 15%, 10%, 9% and 8%, respectively, in both years). The proportion of antibiotic treatments administered for seven days or longer was higher in 2022 (26% vs 23%, p=0.009).ConclusionAlthough patients assessed in 2022 presented more risk factors for HAIs than in 2017, the prevalence of HAIs and of patients receiving antibiotics appears stable between the two years. Further in-depth analysis is needed to better understand these findings.
Source: HAL
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7206716767
FWCI:
Cites:
Cited by:
Related to: 10